IM Cannabis (IMCC) Registration Filing summary

Company overview and business model

• Operates internationally, focusing on medical cannabis markets in Israel and Germany, leveraging a data-driven supply chain and regulatory expertise.

• Shifted strategic focus to Germany after partial legalization in 2024, aiming for significant growth in the expanding medical cannabis sector.

• In Israel, operates licensed pharmacies, online retail, and home delivery, enhancing direct patient access and brand recognition.

• German operations include a logistics center and EU-GMP production facility, repackaging, and third-party services.

Financial performance and metrics

• As of February 2026, received US$2,132,912 in gross proceeds from promissory notes and warrants.

• Capitalization as of September 30, 2025: pro forma as adjusted total equity of C$8,043,000 and total capitalization of C$23,654,000.

• Recent private placements in 2025 and 2026 raised additional capital through convertible notes and warrants.

Use of proceeds and capital allocation

• Net proceeds from promissory notes allocated to debt repayment and general corporate purposes.

• Proceeds from warrant exercises, if any, intended for working capital, debt repayment, and general corporate purposes.